About Careers Internship MedBlog Contact us

Jubilant Life Sciences gets FDA Nod for Anti-Depressant Drug

by Kathy Jones on October 20, 2013 at 7:55 PM
 Jubilant Life Sciences gets FDA Nod for Anti-Depressant Drug

Jubilant Life Sciences has announced that it has received approval from the US Food and Drug Administration (FDA) for its anti-depressant drug Bupropion Hydrochloride.

"We have also received approval for the same extended drug used as smoking cessation aid. Both formulations are generic version of GlaxoSmithKline's Wellbutrin and Zyban tablets respectively," the company said in a statement here.


The market size for the twin products is estimated to be around $518 million annually.

"We propose to launch both the drugs in this quarter of 2013-14," the statement said.

The company has filed 649 applications for formulations till June, of which 189 were approved in different geographies the world over, including 58 abbreviated new drug application (ANDA) in the US and 41 dossier filings in Europe.

With 10 production facilities across India, Canada and the US, Jubilant manufactures and supplies active pharmaceutical ingredients (APIs), generics, specialty pharmaceuticals and life science ingredients, besides providing services in contract manufacturing and drug discovery and development.

Source: IANS
Font : A-A+



Recommended Readings

Latest Lifestyle and Wellness News

Skin Hotspots in Ears & Toes - Safe Haven for Harmful Germs
The skin between the toes and behind the ears can harbor many harmful germs that can cause a variety of skin illnesses.
Work Breaks - Need of the Hour to Counteract Prolonged Sitting
Prolonged sitting among office goers, pose risk of cardiovascular diseases, diabetes, hypertension, and certain types of cancers.
Fear of Garlic Bad Breath? Try Deodorizing Effect of Yogurt
Yogurt's protein and fat content demonstrated its unidentified deodorizing properties against garlic's pungent odor.
Smoking Tobacco and Cannabis Tied to Depression Risk
People who smoke tobacco and cannabis have an increased risk of depression and anxiety than those who use either substance alone or not at all.
Prevent Cognitive Decline in High-Activity Jobs
Research reveals the association between cognitive impairment and physically demanding careers, emphasizing the need for preventative strategies.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Jubilant Life Sciences gets FDA Nod for Anti-Depressant Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests